Charles Daley
Concepts (471)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 100 | 2026 | 339 | 18.150 |
Why?
| | Mycobacterium avium-intracellulare Infection | 29 | 2026 | 63 | 9.530 |
Why?
| | Mycobacterium abscessus | 43 | 2026 | 110 | 9.150 |
Why?
| | Mycobacterium avium Complex | 44 | 2026 | 87 | 8.580 |
Why?
| | Nontuberculous Mycobacteria | 54 | 2026 | 189 | 7.890 |
Why?
| | Lung Diseases | 47 | 2026 | 780 | 7.730 |
Why?
| | Anti-Bacterial Agents | 69 | 2026 | 1922 | 6.500 |
Why?
| | Antitubercular Agents | 39 | 2025 | 208 | 5.270 |
Why?
| | Tuberculosis | 33 | 2025 | 283 | 4.890 |
Why?
| | Tuberculosis, Pulmonary | 26 | 2025 | 127 | 4.350 |
Why?
| | Tuberculosis, Multidrug-Resistant | 14 | 2025 | 47 | 3.440 |
Why?
| | Amikacin | 19 | 2026 | 29 | 3.410 |
Why?
| | Mycobacterium Infections | 12 | 2019 | 55 | 3.160 |
Why?
| | Mycobacterium | 16 | 2026 | 101 | 2.920 |
Why?
| | Mycobacterium kansasii | 10 | 2020 | 14 | 2.850 |
Why?
| | Bronchiectasis | 19 | 2026 | 112 | 2.780 |
Why?
| | Cystic Fibrosis | 22 | 2025 | 1160 | 2.620 |
Why?
| | Mycobacterium tuberculosis | 28 | 2025 | 318 | 2.610 |
Why?
| | Macrolides | 15 | 2023 | 67 | 2.250 |
Why?
| | Interferon-gamma Release Tests | 7 | 2025 | 32 | 1.990 |
Why?
| | Drug Resistance, Bacterial | 21 | 2023 | 185 | 1.860 |
Why?
| | Microbial Sensitivity Tests | 29 | 2026 | 363 | 1.690 |
Why?
| | Sputum | 25 | 2020 | 302 | 1.520 |
Why?
| | Disease Outbreaks | 7 | 2025 | 419 | 1.390 |
Why?
| | Humans | 205 | 2026 | 145140 | 1.300 |
Why?
| | Latent Tuberculosis | 8 | 2017 | 70 | 1.200 |
Why?
| | Pneumonia, Bacterial | 6 | 2017 | 113 | 1.170 |
Why?
| | Drug Therapy, Combination | 22 | 2026 | 1043 | 1.130 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2016 | 130 | 1.100 |
Why?
| | Boron Compounds | 2 | 2026 | 29 | 1.100 |
Why?
| | Antibiotics, Antitubercular | 9 | 2021 | 35 | 1.050 |
Why?
| | Clofazimine | 4 | 2021 | 15 | 1.050 |
Why?
| | Rifampin | 14 | 2024 | 79 | 1.040 |
Why?
| | Ethambutol | 11 | 2026 | 27 | 1.010 |
Why?
| | Clarithromycin | 14 | 2026 | 24 | 0.960 |
Why?
| | Pneumonia | 5 | 2023 | 635 | 0.950 |
Why?
| | Tetracyclines | 1 | 2025 | 16 | 0.920 |
Why?
| | Patient Reported Outcome Measures | 2 | 2026 | 497 | 0.840 |
Why?
| | Treatment Outcome | 35 | 2026 | 11741 | 0.830 |
Why?
| | Oxazolidinones | 3 | 2013 | 17 | 0.820 |
Why?
| | Acetamides | 3 | 2013 | 39 | 0.800 |
Why?
| | HIV Infections | 15 | 2022 | 3186 | 0.770 |
Why?
| | Global Health | 8 | 2018 | 403 | 0.770 |
Why?
| | Fatigue | 1 | 2025 | 363 | 0.770 |
Why?
| | Aged | 57 | 2026 | 26096 | 0.760 |
Why?
| | Tuberculin Test | 6 | 2016 | 36 | 0.720 |
Why?
| | Equipment Contamination | 2 | 2019 | 67 | 0.690 |
Why?
| | Azithromycin | 7 | 2026 | 101 | 0.680 |
Why?
| | Middle Aged | 64 | 2026 | 36126 | 0.680 |
Why?
| | Professional Practice Gaps | 1 | 2020 | 15 | 0.640 |
Why?
| | Imipenem | 7 | 2024 | 16 | 0.620 |
Why?
| | beta-Lactams | 3 | 2026 | 32 | 0.620 |
Why?
| | Adult | 57 | 2026 | 40665 | 0.610 |
Why?
| | Disease Management | 4 | 2021 | 651 | 0.600 |
Why?
| | Female | 82 | 2026 | 78636 | 0.590 |
Why?
| | Male | 82 | 2026 | 72664 | 0.590 |
Why?
| | San Francisco | 10 | 2014 | 60 | 0.560 |
Why?
| | Practice Guidelines as Topic | 9 | 2026 | 1579 | 0.550 |
Why?
| | Molecular Epidemiology | 4 | 2006 | 73 | 0.550 |
Why?
| | Administration, Inhalation | 7 | 2026 | 571 | 0.510 |
Why?
| | Algorithms | 1 | 2025 | 1845 | 0.500 |
Why?
| | Health Care Sector | 2 | 2013 | 26 | 0.480 |
Why?
| | Linezolid | 5 | 2026 | 25 | 0.480 |
Why?
| | Recurrence | 11 | 2025 | 1134 | 0.480 |
Why?
| | Extensively Drug-Resistant Tuberculosis | 2 | 2013 | 6 | 0.470 |
Why?
| | beta-Lactamase Inhibitors | 6 | 2026 | 9 | 0.470 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2019 | 77 | 0.470 |
Why?
| | Nebramycin | 2 | 2025 | 2 | 0.460 |
Why?
| | United States | 32 | 2025 | 16065 | 0.460 |
Why?
| | Phylogeny | 5 | 2021 | 917 | 0.460 |
Why?
| | Genome, Bacterial | 5 | 2021 | 123 | 0.450 |
Why?
| | Lung | 16 | 2024 | 4101 | 0.450 |
Why?
| | World Health Organization | 3 | 2024 | 104 | 0.440 |
Why?
| | Retrospective Studies | 29 | 2025 | 17247 | 0.420 |
Why?
| | Organ Transplantation | 2 | 2024 | 250 | 0.410 |
Why?
| | Drug Synergism | 4 | 2024 | 354 | 0.400 |
Why?
| | Communicable Disease Control | 1 | 2014 | 85 | 0.390 |
Why?
| | Sex Factors | 1 | 2019 | 2099 | 0.390 |
Why?
| | Serologic Tests | 1 | 2012 | 54 | 0.370 |
Why?
| | Quality of Life | 8 | 2026 | 3194 | 0.360 |
Why?
| | Professional Practice | 1 | 2012 | 57 | 0.360 |
Why?
| | Rifabutin | 2 | 2012 | 7 | 0.350 |
Why?
| | Opportunistic Infections | 1 | 2011 | 47 | 0.340 |
Why?
| | Pyrazinamide | 4 | 2021 | 16 | 0.340 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 134 | 0.340 |
Why?
| | Liposomes | 2 | 2026 | 259 | 0.330 |
Why?
| | Cefoxitin | 4 | 2026 | 8 | 0.320 |
Why?
| | Drug Administration Schedule | 8 | 2025 | 781 | 0.320 |
Why?
| | Occupational Health | 1 | 2013 | 211 | 0.310 |
Why?
| | Aged, 80 and over | 15 | 2025 | 8318 | 0.300 |
Why?
| | Occupational Exposure | 1 | 2013 | 355 | 0.290 |
Why?
| | Cross Infection | 2 | 2025 | 260 | 0.290 |
Why?
| | Disease Progression | 8 | 2026 | 2857 | 0.290 |
Why?
| | Diarylquinolines | 3 | 2025 | 16 | 0.280 |
Why?
| | Incidence | 10 | 2019 | 2915 | 0.280 |
Why?
| | Mass Screening | 3 | 2016 | 1354 | 0.280 |
Why?
| | Cardiac Surgical Procedures | 3 | 2019 | 608 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2026 | 2026 | 0.270 |
Why?
| | Double-Blind Method | 5 | 2026 | 2057 | 0.260 |
Why?
| | Directly Observed Therapy | 2 | 2005 | 15 | 0.260 |
Why?
| | Antigens, Bacterial | 5 | 2012 | 126 | 0.260 |
Why?
| | Europe | 3 | 2025 | 416 | 0.260 |
Why?
| | Cefuroxime | 2 | 2024 | 5 | 0.260 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 640 | 0.260 |
Why?
| | Prospective Studies | 16 | 2025 | 8035 | 0.260 |
Why?
| | Tuberculosis, Pleural | 2 | 2003 | 7 | 0.250 |
Why?
| | Health Personnel | 3 | 2014 | 749 | 0.250 |
Why?
| | Treatment Failure | 5 | 2026 | 360 | 0.240 |
Why?
| | Cephalosporins | 2 | 2024 | 45 | 0.240 |
Why?
| | Morbidity | 2 | 2019 | 322 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2767 | 0.240 |
Why?
| | Suspensions | 1 | 2026 | 28 | 0.240 |
Why?
| | Genomics | 4 | 2021 | 819 | 0.230 |
Why?
| | Administration, Oral | 4 | 2025 | 862 | 0.220 |
Why?
| | Phage Therapy | 1 | 2025 | 17 | 0.220 |
Why?
| | ROC Curve | 4 | 2020 | 617 | 0.220 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 107 | 0.220 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1505 | 0.220 |
Why?
| | Oxazepines | 2 | 2025 | 5 | 0.220 |
Why?
| | Benzoxazoles | 2 | 2025 | 20 | 0.220 |
Why?
| | Peptidyl Transferases | 2 | 2024 | 8 | 0.220 |
Why?
| | Mutation | 5 | 2019 | 4071 | 0.220 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 46 | 0.220 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 69 | 0.210 |
Why?
| | Water Microbiology | 1 | 2005 | 84 | 0.210 |
Why?
| | DNA Fingerprinting | 1 | 2004 | 28 | 0.210 |
Why?
| | Contact Tracing | 1 | 2004 | 26 | 0.210 |
Why?
| | Arizona | 1 | 2024 | 80 | 0.210 |
Why?
| | Boronic Acids | 1 | 2024 | 36 | 0.210 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2005 | 93 | 0.200 |
Why?
| | Research | 2 | 2018 | 430 | 0.200 |
Why?
| | Adolescent | 19 | 2025 | 22479 | 0.200 |
Why?
| | DNA, Bacterial | 3 | 2021 | 320 | 0.200 |
Why?
| | Self Administration | 1 | 2004 | 122 | 0.200 |
Why?
| | Risk Factors | 9 | 2019 | 10857 | 0.200 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.200 |
Why?
| | Mexico | 1 | 2024 | 232 | 0.200 |
Why?
| | Time Factors | 8 | 2026 | 7107 | 0.200 |
Why?
| | Biomedical Research | 5 | 2020 | 717 | 0.200 |
Why?
| | Colorado | 5 | 2024 | 4538 | 0.190 |
Why?
| | London | 1 | 2023 | 46 | 0.190 |
Why?
| | Biomarkers | 3 | 2020 | 4282 | 0.190 |
Why?
| | Leprostatic Agents | 1 | 2022 | 6 | 0.190 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 189 | 0.190 |
Why?
| | Clinical Trials as Topic | 5 | 2026 | 1058 | 0.190 |
Why?
| | Republic of Korea | 6 | 2019 | 43 | 0.190 |
Why?
| | Young Adult | 12 | 2025 | 14176 | 0.180 |
Why?
| | Forced Expiratory Volume | 6 | 2025 | 450 | 0.180 |
Why?
| | Pneumonectomy | 2 | 2016 | 167 | 0.180 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.180 |
Why?
| | Registries | 5 | 2020 | 2401 | 0.180 |
Why?
| | Spectinomycin | 1 | 2021 | 2 | 0.180 |
Why?
| | Isoniazid | 4 | 2019 | 70 | 0.180 |
Why?
| | Thorax | 1 | 2022 | 51 | 0.170 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2662 | 0.170 |
Why?
| | Radiography, Thoracic | 3 | 2017 | 172 | 0.170 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3410 | 0.170 |
Why?
| | Psychometrics | 1 | 2025 | 731 | 0.170 |
Why?
| | Comorbidity | 4 | 2019 | 1657 | 0.170 |
Why?
| | Cohort Studies | 8 | 2020 | 5988 | 0.160 |
Why?
| | Safety | 1 | 2003 | 357 | 0.160 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 6 | 0.160 |
Why?
| | Sensitivity and Specificity | 5 | 2025 | 1995 | 0.160 |
Why?
| | Cluster Analysis | 4 | 2020 | 500 | 0.160 |
Why?
| | Respiratory Therapy | 1 | 2020 | 25 | 0.160 |
Why?
| | Serine Proteases | 1 | 2020 | 26 | 0.160 |
Why?
| | Bacteriophages | 1 | 2022 | 110 | 0.160 |
Why?
| | Prevalence | 4 | 2019 | 2855 | 0.150 |
Why?
| | Child | 13 | 2025 | 22670 | 0.150 |
Why?
| | Area Under Curve | 3 | 2020 | 329 | 0.150 |
Why?
| | Nitroimidazoles | 1 | 2019 | 16 | 0.150 |
Why?
| | Mycobacterium fortuitum | 1 | 2019 | 2 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2020 | 5411 | 0.150 |
Why?
| | Oxazoles | 1 | 2019 | 48 | 0.150 |
Why?
| | Durable Medical Equipment | 1 | 2019 | 5 | 0.150 |
Why?
| | Genotyping Techniques | 1 | 2019 | 71 | 0.150 |
Why?
| | Bronchoscopy | 1 | 2020 | 227 | 0.150 |
Why?
| | Cost of Illness | 1 | 2021 | 324 | 0.140 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6055 | 0.140 |
Why?
| | Genotype | 6 | 2019 | 1844 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 261 | 0.140 |
Why?
| | Patient Selection | 1 | 2003 | 733 | 0.140 |
Why?
| | DNA Gyrase | 1 | 2018 | 8 | 0.140 |
Why?
| | Azabicyclo Compounds | 3 | 2024 | 7 | 0.140 |
Why?
| | Aza Compounds | 2 | 2010 | 12 | 0.140 |
Why?
| | Respiratory System Agents | 1 | 2018 | 22 | 0.140 |
Why?
| | Internationality | 1 | 2019 | 156 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.140 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4552 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 195 | 0.130 |
Why?
| | Patient Compliance | 3 | 2011 | 587 | 0.130 |
Why?
| | Musculoskeletal Diseases | 1 | 2019 | 90 | 0.130 |
Why?
| | Tuberculosis Vaccines | 2 | 2010 | 4 | 0.130 |
Why?
| | Anti-HIV Agents | 3 | 2016 | 908 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 698 | 0.130 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2018 | 61 | 0.130 |
Why?
| | Pulmonary Medicine | 1 | 2018 | 78 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 103 | 0.130 |
Why?
| | Salvage Therapy | 1 | 2018 | 165 | 0.130 |
Why?
| | Elephants | 1 | 2017 | 7 | 0.130 |
Why?
| | Interferon-gamma | 4 | 2007 | 784 | 0.130 |
Why?
| | Agammaglobulinemia | 1 | 2017 | 36 | 0.130 |
Why?
| | Fluoroquinolones | 3 | 2018 | 44 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 238 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 8 | 0.120 |
Why?
| | Quinolines | 2 | 2010 | 190 | 0.120 |
Why?
| | Kartagener Syndrome | 1 | 2016 | 31 | 0.120 |
Why?
| | Staphylococcal Infections | 2 | 2018 | 390 | 0.120 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 65 | 0.120 |
Why?
| | Prognosis | 5 | 2020 | 4310 | 0.120 |
Why?
| | Genes, Bacterial | 1 | 2016 | 152 | 0.120 |
Why?
| | Levofloxacin | 1 | 2016 | 21 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 483 | 0.120 |
Why?
| | Cough | 3 | 2023 | 123 | 0.110 |
Why?
| | Public Health | 4 | 2016 | 571 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2588 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 329 | 0.110 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 130 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1763 | 0.110 |
Why?
| | Chronic Disease | 3 | 2023 | 1806 | 0.110 |
Why?
| | Drug Tolerance | 1 | 2015 | 99 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2016 | 266 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2014 | 776 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2026 | 196 | 0.100 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2007 | 279 | 0.100 |
Why?
| | DNA Transposable Elements | 2 | 2006 | 124 | 0.100 |
Why?
| | Genetic Variation | 2 | 2021 | 967 | 0.100 |
Why?
| | Peptidoglycan | 2 | 2026 | 28 | 0.100 |
Why?
| | beta-Lactamases | 2 | 2026 | 53 | 0.100 |
Why?
| | CD4 Lymphocyte Count | 2 | 2004 | 280 | 0.100 |
Why?
| | MicroRNAs | 1 | 2020 | 686 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 477 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 669 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 881 | 0.100 |
Why?
| | Societies, Medical | 4 | 2020 | 898 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2018 | 547 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 531 | 0.090 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.090 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2015 | 337 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.090 |
Why?
| | Transcriptome | 2 | 2015 | 1029 | 0.090 |
Why?
| | Glycolipids | 1 | 2012 | 53 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 671 | 0.090 |
Why?
| | Cytokines | 2 | 2011 | 2048 | 0.090 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 147 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1742 | 0.090 |
Why?
| | Drug Resistance, Multiple | 1 | 2011 | 25 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2003 | 138 | 0.080 |
Why?
| | Immunoglobulin A | 1 | 2012 | 214 | 0.080 |
Why?
| | Drug Interactions | 1 | 2012 | 404 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 919 | 0.080 |
Why?
| | Debridement | 1 | 2011 | 85 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 968 | 0.080 |
Why?
| | Virulence | 1 | 2011 | 278 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 149 | 0.080 |
Why?
| | Hospitals, General | 2 | 2014 | 25 | 0.080 |
Why?
| | Animals | 8 | 2025 | 37952 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 394 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2020 | 3616 | 0.080 |
Why?
| | Hepatitis, Viral, Human | 1 | 2009 | 21 | 0.080 |
Why?
| | Netherlands | 2 | 2012 | 82 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18303 | 0.070 |
Why?
| | Bacteriological Techniques | 1 | 2009 | 66 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2015 | 330 | 0.070 |
Why?
| | Forkhead Transcription Factors | 2 | 2007 | 207 | 0.070 |
Why?
| | Interleukins | 2 | 2007 | 248 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2026 | 362 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2012 | 329 | 0.070 |
Why?
| | Vitamins | 1 | 2010 | 182 | 0.070 |
Why?
| | Early Diagnosis | 1 | 2009 | 251 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1325 | 0.070 |
Why?
| | Radiography | 2 | 2008 | 852 | 0.070 |
Why?
| | RNA, Ribosomal, 23S | 2 | 2018 | 12 | 0.070 |
Why?
| | Interleukin-9 | 1 | 2007 | 11 | 0.070 |
Why?
| | Child, Preschool | 4 | 2016 | 11835 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 2133 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2458 | 0.070 |
Why?
| | Survival Analysis | 2 | 2016 | 1371 | 0.070 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 33 | 0.060 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2007 | 9 | 0.060 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 69 | 0.060 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2007 | 47 | 0.060 |
Why?
| | Congresses as Topic | 2 | 2020 | 223 | 0.060 |
Why?
| | Th1 Cells | 1 | 2007 | 139 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2136 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 403 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 522 | 0.060 |
Why?
| | Liver Function Tests | 2 | 2003 | 105 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2007 | 269 | 0.060 |
Why?
| | Age Factors | 3 | 2019 | 3338 | 0.060 |
Why?
| | Japan | 1 | 2026 | 148 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2026 | 147 | 0.060 |
Why?
| | Keratosis | 1 | 2025 | 16 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 998 | 0.060 |
Why?
| | Hydrotherapy | 1 | 2005 | 7 | 0.060 |
Why?
| | Penicillin-Binding Proteins | 1 | 2024 | 2 | 0.060 |
Why?
| | Bacterial Load | 1 | 2025 | 67 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 837 | 0.050 |
Why?
| | Microbial Viability | 1 | 2025 | 83 | 0.050 |
Why?
| | Coinfection | 2 | 2018 | 143 | 0.050 |
Why?
| | Antirheumatic Agents | 1 | 2007 | 307 | 0.050 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 251 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 177 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 640 | 0.050 |
Why?
| | Biopsy | 2 | 2005 | 1079 | 0.050 |
Why?
| | Mycobacterium xenopi | 2 | 2014 | 2 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 2016 | 543 | 0.050 |
Why?
| | Streptomycin | 1 | 2003 | 18 | 0.050 |
Why?
| | Delphi Technique | 1 | 2026 | 330 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 119 | 0.050 |
Why?
| | Carrier State | 1 | 2004 | 78 | 0.050 |
Why?
| | Influenza, Human | 1 | 2009 | 624 | 0.050 |
Why?
| | Dust | 1 | 2023 | 92 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 410 | 0.050 |
Why?
| | Pseudomonas Infections | 2 | 2016 | 230 | 0.050 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 451 | 0.050 |
Why?
| | Medicare | 2 | 2019 | 902 | 0.050 |
Why?
| | Substance Abuse, Intravenous | 1 | 2004 | 127 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2007 | 1216 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2004 | 231 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 2115 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1488 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2024 | 180 | 0.040 |
Why?
| | Los Angeles | 1 | 2002 | 73 | 0.040 |
Why?
| | Survival Rate | 1 | 2007 | 2087 | 0.040 |
Why?
| | Lactams | 1 | 2021 | 28 | 0.040 |
Why?
| | Drug Costs | 1 | 2003 | 117 | 0.040 |
Why?
| | Amoxicillin | 1 | 2022 | 35 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5886 | 0.040 |
Why?
| | Phenotype | 2 | 2021 | 3138 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 263 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 962 | 0.040 |
Why?
| | Carboxypeptidases | 1 | 2020 | 12 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 337 | 0.040 |
Why?
| | Water | 1 | 2023 | 445 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 74 | 0.040 |
Why?
| | Gene Ontology | 1 | 2020 | 53 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2005 | 608 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1546 | 0.040 |
Why?
| | Chimera | 1 | 2019 | 60 | 0.040 |
Why?
| | Medication Adherence | 1 | 2024 | 540 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 207 | 0.040 |
Why?
| | Neutrophils | 1 | 2025 | 1123 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 624 | 0.040 |
Why?
| | Meat | 1 | 2019 | 64 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 608 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1261 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 103 | 0.040 |
Why?
| | Population Surveillance | 1 | 2002 | 484 | 0.030 |
Why?
| | Risk Assessment | 2 | 2019 | 3740 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 2018 | 93 | 0.030 |
Why?
| | Prosthesis-Related Infections | 1 | 2019 | 98 | 0.030 |
Why?
| | Insurance Claim Review | 1 | 2018 | 83 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2019 | 136 | 0.030 |
Why?
| | Gene Expression | 2 | 2016 | 1474 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 847 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 197 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 317 | 0.030 |
Why?
| | Animals, Zoo | 1 | 2017 | 15 | 0.030 |
Why?
| | Drug Monitoring | 2 | 2016 | 399 | 0.030 |
Why?
| | Methyltransferases | 1 | 2017 | 75 | 0.030 |
Why?
| | Otitis | 1 | 2016 | 9 | 0.030 |
Why?
| | Pseudomonas | 1 | 2016 | 30 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2016 | 64 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 946 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2017 | 161 | 0.030 |
Why?
| | Micronesia | 1 | 2016 | 7 | 0.030 |
Why?
| | Mycobacterium chelonae | 1 | 2016 | 8 | 0.030 |
Why?
| | Spirometry | 1 | 2016 | 233 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 361 | 0.030 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2016 | 23 | 0.030 |
Why?
| | Vital Capacity | 1 | 2016 | 292 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2016 | 197 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 105 | 0.030 |
Why?
| | Needs Assessment | 1 | 2018 | 401 | 0.030 |
Why?
| | Bronchi | 1 | 2017 | 263 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 396 | 0.030 |
Why?
| | Uganda | 1 | 2015 | 89 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 573 | 0.030 |
Why?
| | Rhinitis | 1 | 2016 | 169 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 554 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2016 | 236 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1132 | 0.030 |
Why?
| | Sinusitis | 1 | 2016 | 227 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 310 | 0.030 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2013 | 156 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2015 | 2803 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2014 | 123 | 0.020 |
Why?
| | Consensus | 1 | 2016 | 478 | 0.020 |
Why?
| | Mycobacterium avium | 1 | 2013 | 21 | 0.020 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2012 | 7 | 0.020 |
Why?
| | Mycolic Acids | 1 | 2012 | 6 | 0.020 |
Why?
| | Greece | 1 | 2012 | 9 | 0.020 |
Why?
| | Geography | 1 | 2013 | 185 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2012 | 40 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 867 | 0.020 |
Why?
| | Iran | 1 | 2012 | 44 | 0.020 |
Why?
| | Italy | 1 | 2012 | 114 | 0.020 |
Why?
| | Sweden | 1 | 2012 | 113 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2012 | 62 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 88 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 545 | 0.020 |
Why?
| | Developing Countries | 2 | 2005 | 316 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 139 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Microspheres | 1 | 2011 | 141 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 153 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 320 | 0.020 |
Why?
| | Demography | 1 | 2011 | 282 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2015 | 560 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 395 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1048 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 490 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2437 | 0.020 |
Why?
| | Postoperative Care | 1 | 2012 | 286 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 507 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2016 | 862 | 0.020 |
Why?
| | Hepatitis, Chronic | 1 | 2009 | 5 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1470 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 380 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 402 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 386 | 0.020 |
Why?
| | Pleural Diseases | 1 | 2009 | 23 | 0.020 |
Why?
| | Fatty Acids | 1 | 2012 | 457 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1117 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1454 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 554 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2009 | 175 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2881 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 61 | 0.020 |
Why?
| | Lymphatic Diseases | 1 | 2007 | 21 | 0.020 |
Why?
| | Urinalysis | 1 | 2007 | 83 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 296 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1537 | 0.020 |
Why?
| | Bone Diseases | 1 | 2007 | 61 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2006 | 10 | 0.010 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 96 | 0.010 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2010 | 371 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2949 | 0.010 |
Why?
| | Africa | 1 | 2006 | 118 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 659 | 0.010 |
Why?
| | Infection Control | 1 | 2007 | 173 | 0.010 |
Why?
| | Skin Diseases | 1 | 2007 | 152 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2007 | 422 | 0.010 |
Why?
| | Asthma | 1 | 2016 | 1795 | 0.010 |
Why?
| | India | 1 | 2005 | 213 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 846 | 0.010 |
Why?
| | Virus Latency | 1 | 2005 | 90 | 0.010 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 232 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2007 | 496 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 692 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 2012 | 960 | 0.010 |
Why?
| | Cost Savings | 1 | 2004 | 86 | 0.010 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2003 | 5 | 0.010 |
Why?
| | Pleura | 1 | 2003 | 28 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 2003 | 29 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2004 | 221 | 0.010 |
Why?
| | Pleural Effusion | 1 | 2003 | 59 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 119 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2928 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 527 | 0.010 |
Why?
| | Infant | 1 | 2016 | 10060 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2003 | 280 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5972 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 368 | 0.010 |
Why?
| | Health Policy | 1 | 2004 | 400 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2004 | 556 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1955 | 0.010 |
Why?
| | Rural Population | 1 | 2005 | 657 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1893 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|